BCR-ABL directed immunotherapy: a virtual reality?

abstract：:Normal, bi-directional interactions between CD 40 and its natural ligand CD 154 (CD 40 ligand) are central to the generation of both T cell-dependent, humoral immune responses and cytotoxic T-cell responses. CD 40 is expressed on a broad range of hematological and epithelial malignancies. The development of monoclonal...

journal_title：Leukemia & lymphoma

authors： Geldart T,Illidge T

更新日期：2005-08-01 00:00:00

abstract：:Permanently established human cell lines can produce several retroviruses. It is important to routinely test such cell lines for human T cell lymphotropic virus (HTLV) type I and II, and for human immunodeficiency virus (HIV) type 1 and 2 in order to exclude any potential biohazard from cell lines producing human retr...

journal_title：Leukemia & lymphoma

authors： Häne BG,Drexler HG

更新日期：1993-10-01 00:00:00

abstract：:The mammalian target of rapamycin (mTOR) pathway is a major therapeutic target in the treatment of hematological malignancies, as it controls cellular events of high importance for regulation of mRNA translation and protein production. Rapalogs, or first-generation mTOR inhibitors, have produced only modest clinical b...

journal_title：Leukemia & lymphoma

authors： Mohindra NA,Platanias LC

更新日期：2015-01-01 00:00:00

abstract：:The classification of germinal centre (GC) and non-GC is an important prognostic immunophenotype for patients with diffuse large B cell lymphoma (DLBCL) following anthracycline-based chemotherapy. The expression of the anti-apoptotic protein, Bcl-2, has been associated with an unfavourable prognosis in patients with D...

journal_title：Leukemia & lymphoma

authors： Song MK,Chung JS,Shin DH,Seol YM,Shin HJ,Choi YJ,Cho GJ

更新日期：2009-01-01 00:00:00

abstract：:Granulocyte-colony stimulating factors (G-CSFs) enhance bone marrow (BM) recovery after autologous stem cell transplant (ASCT) in patients with lymphoma and myeloma. Few publications exist that discuss the use of filgrastim biosimilars after ASCT. We conducted a single-center retrospective study in patients with lymph...

journal_title：Leukemia & lymphoma

authors： Ianotto JC,Ngo Sack F,Couturier MA,Tempescul A,Mugnier N,Delepine P,Guillerm G,Berthou C

更新日期：2014-01-01 00:00:00

abstract：:This phase-I/phase-II study evaluated panobinostat in combination with ifosfamide, carboplatin, etoposide (P-ICE) in relapsed/refractory classical Hodgkin lymphoma. During phase I, panobinostat was given daily on Monday/Wednesday/Friday starting one week prior to Cycle 1 (C1) of ICE and during two weeks of C1-2 of ICE...

journal_title：Leukemia & lymphoma

authors： Hu B,Younes A,Westin JR,Turturro F,Claret L,Feng L,Fowler N,Neelapu S,Romaguera J,Hagemeister FB,Rodriguez MA,Samaniego F,Fayad LE,Copeland AR,Nastoupil LJ,Nieto Y,Fanale MA,Oki Y

更新日期：2018-04-01 00:00:00

abstract：:We evaluated the prognostic role of 18FDG-PET performed before ASCT in patients affected by lymphoma who underwent high-dose chemotherapy followed by ASCT as first-line treatment for high-risk disease or as second-line or more for relapsed or refractory disease. We retrospectively analyzed 53 consecutive patients, 14 ...

journal_title：Leukemia & lymphoma

authors： Crocchiolo R,Canevari C,Assanelli A,Lunghi F,Tassara M,Stanghellini ML,Clerici D,Landoni C,Servida P,Bernardi M,Peccatori J,Ferreri A,Gianolli L,Bordignon C,Caligaris-Cappio F,Ciceri F,Fazio F

更新日期：2008-04-01 00:00:00

abstract：:The transcriptional factor SOX11 is a disease-defining antigen in mantle cell lymphoma (MCL) and absent in most non-malignant tissues. To explore the role of SOX11-related cell signaling, and potentially take benefit from these for targeted therapy, associated networks and proteins need to be defined. In this study, w...

journal_title：Leukemia & lymphoma

authors： Kuci V,Nordström L,Conrotto P,Ek S

更新日期：2016-08-01 00:00:00

abstract：:Immunotherapy in the form of allogeneic stem cell transplantation (SCT) plays an instrumental role in the treatment of acute myeloid leukemia (AML), with non-transplant modalities of immunotherapy including checkpoint blockade now being actively explored. Here, we provide an overview of the graft versus leukemia (GVL)...

journal_title：Leukemia & lymphoma

authors： Knorr DA,Goldberg AD,Stein EM,Tallman MS

更新日期：2019-12-01 00:00:00

abstract：:Between 1985 and 1990, the French Cooperative Group on Chronic Lymphocytic Leukemia (CLL) randomized 287 stage B patients between intermittent chlorambucil plus prednisone (n = 140) or CHOP (n = 147), and 90 stage C patients between CHOP (n = 44) or CHOP plus methotrexate (n = 46). In stage B, although treatment respo...

journal_title：Leukemia & lymphoma

authors：

更新日期：1994-05-01 00:00:00

abstract：:Multiple myeloma is a B-cell malignancy with a highly variable outcome. Despite the marked recent improvements in its management, especially due to the widespread application of high-dose treatment and autologous stem cell transplantation, relapses eventually occur in the majority of patients. Systematic research at U...

journal_title：Leukemia & lymphoma

authors： Fassas AB,Van Rhee F,Tricot G

更新日期：2003-05-01 00:00:00

abstract：:One hundred and seventy-five hemato-oncologists and nuclear medicine specialists from 23 countries joined the 2-day 4th International Workshop on Positron Emission Tomography in Lymphoma held in October 2012. The meeting was under the auspices of the European Lymphoma Institute, the Lymphoma Study Association (LYSA) a...

journal_title：Leukemia & lymphoma

authors： Meignan M,Barrington S,Itti E,Gallamini A,Haioun C,Polliack A

更新日期：2014-01-01 00:00:00

abstract：:A recent phase III trial demonstrated improved progression-free survival (PFS) and overall survival (OS) associated with adding rituximab to fludarabine and cyclophosphamide (R-FC) compared to FC in treatment of previously untreated chronic lymphocytic leukemia (CLL). A cost-effectiveness analysis of R-FC over FC was ...

journal_title：Leukemia & lymphoma

authors： Hornberger J,Reyes C,Shewade A,Lerner S,Friedmann M,Han L,Gutierrez H,Satram-Hoang S,Keating MJ

更新日期：2012-02-01 00:00:00

abstract：:The MRC has conducted randomised trials in CLL sine 1978: CLL 1 (1978-84), 660 patients; CLL 2 (1984-90), 640 patients; CLL 3 (from June 1990), 90 patients. Centralised morphological diagnosis and membrane marker studies have allowed the exclusion of non-CLL disorders. Some of the treatment questions were repeated in ...

journal_title：Leukemia & lymphoma

authors： Catovsky D,Richards S,Fooks J,Hamblin TJ

更新日期：1991-01-01 00:00:00

abstract：:Fusarium infection is rare but important infection after bone marrow transplantation (BMT). A 27-year-old man developed systemic fusarial infection following severe skin damage probably caused by high-dose thiotepa administration. Systemic fusariosis rapidly progressed to a variety of organs despite antifungal treatme...

journal_title：Leukemia & lymphoma

authors： Miyazaki M,Miyakoshi S,Kami M,Mori M,Kishi Y,Inagawa H,Machida U,Matsumura T,Kawagoe S,Ueyama J,Morinaga S,Matsushita H,Muto Y

更新日期：2001-01-01 00:00:00

abstract：:Recent data have elucidated the pathogenesis of transient abnormal myelopoiesis (TAM) to a great extent. TAM is a monoclonal disorder which resolves spontaneously and the target cell in this disorder is a multipotent stem cell which is capable of differentiating into megakaryocytes. The pathogeneses of TAM/AMKL (acute...

journal_title：Leukemia & lymphoma

authors： Kurahashi H,Hara J,Yumura-Yagi K,Tawa A,Kawa-Ha K

更新日期：1992-12-01 00:00:00

abstract：:High-dose melphalan (HDM) followed by autologous hematopoietic cell transplantation (auto-HCT) remains the standard-of-care therapy for multiple myeloma (MM) even with the availability of proteasome inhibitors and immunomodulatory drugs. Gastrointestinal (GI) toxicity is the main cause of morbidity after HDM. Amifosti...

journal_title：Leukemia & lymphoma

authors： Malek E,Gupta V,Creger R,Caimi P,Vatsayan A,Covut F,Bashir Q,Champlin R,Delgado R,Rondon G,Cooper B,de Lima M,Lazarus HM,Qazilbash M

更新日期：2018-08-01 00:00:00

abstract：:Immunomodulatory drugs (IMiDs) may favor autoimmune disease (AD) occurrence. We conducted a retrospective study to evaluate AD occurrence among IMiD-treated patients with myeloma. Patients were grouped into three classes depending on the type of IMiD engaged. The first group included patients treated with thalidomide ...

journal_title：Leukemia & lymphoma

authors： Montefusco V,Galli M,Spina F,Stefanoni P,Mussetti A,Perrone G,De Philippis C,Dalto S,Maura F,Bonini C,Rezzonico F,Pennisi M,Roncari L,Soldarini M,Dodero A,Farina L,Cocito F,Caprioli C,Corradini P

更新日期：2014-09-01 00:00:00

abstract：:Diffuse large B-cell lymphoma (DLBCL) is a high-grade lymphoma that requires treatment. We retrospectively analyzed the impact of time from diagnosis-to-treatment (TDT) on progression-free survival (PFS) and overall survival (OS) in 581 R-CHOP-treated patients. TDT was defined as the interval between diagnostic biopsy...

journal_title：Leukemia & lymphoma

authors： Phipps C,Lee YS,Ying H,Nagarajan C,Grigoropoulos N,Chen Y,Tang T,Goh AZ,Ghosh A,Ng HJ,Gopalakrishnan S,Loh Y,Lim ST,Hwang W,Tan D,Goh YT

更新日期：2018-10-01 00:00:00

abstract：:Treatment of hairy cell leukemia (HCL), a disease first described in 1958, has evolved from splenectomy, which resulted in a normalization of blood counts in about 41% of patients and an improvement in the remaining 59% of patients but with a time to failure of only approximately 19 months, through treatment in the ea...

journal_title：Leukemia & lymphoma

authors： Golomb HM

更新日期：2011-06-01 00:00:00

abstract：:To define the specific genetic alterations in nasal natural killer/T-cell lymphoma (N-NK/T-L), the assay of restriction landmark genomic scanning (RLGS), a genome-wide method, was used to investigate a pair of genomic DNA from N-NK/T-L cells and peripheral blood leukocytes of the same patient. The intensified spots in...

journal_title：Leukemia & lymphoma

authors： Ye Y,Li T,Zhang B,Guo Z

更新日期：2007-01-01 00:00:00

abstract：:Baseline anemia is a relevant prognostic factor in the overall population of non-Hodgkin's lymphoma (NHL) patients, and studies focusing on elderly NHL are awaited. We conducted a pooled analysis of a cohort of comparable patients enrolled (1993 - 2001) in three multicenter clinical trials on use of a MACOP-B-like reg...

journal_title：Leukemia & lymphoma

authors： Zinzani PL,Tani M,Alinari L,Molinari AL,Stefoni V,Visani G,Gentilini P,Guardigni L,Fina M,Baccarani M

更新日期：2005-10-01 00:00:00

abstract：:In 90 splenectomized patients with active HCL, this multi-institutional intergroup study showed that as compared to alpha interferon (aIF), pentostatin resulted in a higher incidence of response, but the difference was not statistically significantly. Pentostatin-induced remissions occurred significantly faster and su...

journal_title：Leukemia & lymphoma

authors： Rai KR

更新日期：1994-01-01 00:00:00

abstract：:We aimed to identify whether the use of autologous hematopoietic cell transplantation (HCT) impacts outcomes for multiple myeloma patients with gains of chromosome 1q (+1q). We retrospectively identified 95 patients, 21% having +1q. For patients with +1q, the overall response rate to induction was 85%, with 40% having...

journal_title：Leukemia & lymphoma

authors： Shah GL,Landau H,Londono D,Devlin SM,Kosuri S,Lesokhin AM,Lendvai N,Hassoun H,Chung DJ,Koehne G,Jhanwar SC,Landgren O,Levine R,Giralt SA

更新日期：2017-08-01 00:00:00

abstract：:Anamorsin is a cell-death-defying factor, which was originally isolated as a molecule that conferred resistance to apoptosis induced by growth factor starvation. In order to evaluate anamorsin expression levels in malignant lymphoma, we immunostained paraffin-embedded sections with anti-anamorsin monoclonal antibodies...

journal_title：Leukemia & lymphoma

authors： Shizusawa T,Shibayama H,Murata S,Saitoh Y,Sugimoto Y,Matsumura I,Ogawa H,Sugiyama H,Fukuhara S,Hino M,Kanamaru A,Yamauchi A,Aozasa K,Kanakura Y

更新日期：2008-01-01 00:00:00

abstract：:Analysis of the microRNA transcriptome following dexa- methasone treatment of the acute lymphocytic leukemia (ALL) cell line RS4;11 showed a global down-regulation of microRNA levels. MIR17HG was rapidly down-regulated following treatment, with chromatin immunoprecipitation (ChIP) analysis demonstrating the promoter t...

journal_title：Leukemia & lymphoma

authors： Harada M,Pokrovskaja-Tamm K,Söderhäll S,Heyman M,Grander D,Corcoran M

更新日期：2012-10-01 00:00:00

abstract：:Bullous pyoderma gangrenosum begins as a bulla, nodule or nonulcerated erythematous plaque that blisters or ulcerates to form a superficial ulcer surrounded by a hemorrhagic, bullous border, which is surrounded by a blue-gray halo. Bullous pyoderma gangrenosum is most commonly associated with hematologic malignancies,...

journal_title：Leukemia & lymphoma

authors： Fox LP,Geyer AS,Husain S,Grossman ME

更新日期：2006-01-01 00:00:00

abstract：:We investigated 41 diffuse large B-cell lymphomas (DLBCL) diagnosed at one center harboring ≥50% of latently Epstein-Barr virus (EBV)-infected neoplastic cells occurring in 34 patients aged ≥50 years and in 7 patients younger than 50 years in the absence of any known immunodeficiency for the expression patterns of EBV...

journal_title：Leukemia & lymphoma

authors： Jöhrens K,Trappe RU,Lenze D,Pfreundschuh M,Ziepert M,Hummel M,Anagnostopoulos I

更新日期：2016-12-01 00:00:00

abstract：:This study was conducted to compare the results of myeloablative therapy followed either by autologous stem cell transplantation (SCT) or allogeneic SCT for poor-risk low-grade non-Hodgkin's lymphoma. Eighteen patients received autologous SCT and 15 patients received allogeneic SCT. All autologous patients had chemose...

journal_title：Leukemia & lymphoma

authors： Verdonck LF

更新日期：1999-06-01 00:00:00

abstract：:In a prospective multicenter study 68 out of 158 patients with HIV infection and malignant lymphoma were assigned to a risk-adapted induction therapy using the following algorithm: High-risk patients fulfilled 2 of 3 criteria: T4 lymphocytes <50/microL; WHO activity index 3 or 4; pre-existing AIDS-defining opportunist...

journal_title：Leukemia & lymphoma

authors： Weiss R,Huhn D,Mitrou P,Nerl C,Schürmann D,Scheidegger C,Knauf W,Trenn G,Kronawitter U,Van Lunzen J,Arastéh K,Herbst H

更新日期：1998-03-01 00:00:00